Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lead to investments with limited upside or potential downside [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify promising candidates [3] Group 2: Case Study - Enhabit (EHAB) - Enhabit (EHAB) has shown a price increase of 1.6% over the past four weeks, indicating growing investor interest [4] - The stock has gained 10.7% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [5] - EHAB has a beta of 1.69, suggesting it moves 69% more than the market in either direction, indicating fast-paced momentum [5] Group 3: Valuation and Earnings Estimates - EHAB has a Momentum Score of B, suggesting it is an opportune time to invest in the stock [6] - The stock has a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which typically attract more investor interest [7] - EHAB is trading at a Price-to-Sales ratio of 0.42, indicating it is relatively undervalued, as investors pay only 42 cents for each dollar of sales [7] Group 4: Additional Opportunities - Besides EHAB, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies to help identify potential winning stock picks based on various investing styles [9]

Summary of The Pennant Group FY Conference Call Company Overview - **Company**: The Pennant Group (NasdaqGS:PNTG) - **Industry**: Home health and hospice services, senior living facilities Key Points and Arguments 1. Growth and Acquisitions - The Pennant Group had a productive year in 2025, starting with the second tranche of the Signature acquisition and culminating in the purchase of a large portfolio from UnitedHealth and Amedisys [25][26] - The company emphasizes investment in leadership, which has led to organic growth in operations, surpassing previous performance levels [27][28] 2. Integration Process - The integration of new acquisitions involves a structured approach focusing on leadership readiness, operational health, and the opportunity presented by the acquisition [31][32] - A typical optimization process post-acquisition spans about nine quarters, involving technology integration and rebranding efforts [33][34] 3. Financial Management - The company expects G&A costs to normalize from approximately 6.7% to 6.5% by the end of 2026, despite initial increases due to acquisitions [36][37] - Current leverage is around two times net debt to adjusted EBITDA, with a comfortable range of two to two and a half times for future acquisitions [39][40] 4. Referral Dynamics and Partnerships - The partnership with Ensign has provided operational benefits, including shared expertise and clinical collaboration, although referrals from Ensign's skilled nursing operations remain low [46][47] - The company is exploring joint venture opportunities with health systems to enhance care delivery and improve clinical outcomes [66][67] 5. Reimbursement and Quality Measures - The Pennant Group has achieved a 4.1 CMS Star Rating, which has helped reduce the differential between Medicare Advantage (MA) rates and fee-for-service rates to 20-25% [58][59] - The company is focused on driving down costs while maintaining quality, which is crucial for negotiations with payers [61][62] 6. Hospice Operations - The company sees potential for growth in hospice length of stay, currently just under 100 days, with a target to improve without exceeding caps [76][77] - The hospice segment is expected to grow in the mid to high single digits, with a focus on maintaining quality care [78][79] 7. Senior Living Performance - The senior living segment has seen high occupancy rates and successful rate increases, attributed to capital investments and improved service offerings [88][89] - The company aims to increase the proportion of healthcare services provided, currently at 20-25%, with a long-term goal of 25-33% [91][92] 8. Labor and Staffing - The company has made significant improvements in caregiver onboarding and retention, leading to decreased turnover and enhanced employee experience [94] - Current staffing levels are sufficient to support increased occupancy, with ongoing efforts to scale as demand grows [94] 9. Future Outlook - The Pennant Group is targeting a 15% margin in senior living, with expectations that increased occupancy and operational efficiencies will contribute to this goal [96][97] Additional Important Insights - The company is actively involved in discussions with CMS regarding reimbursement methodologies, emphasizing the importance of home health services in the continuum of care [71][72] - The focus on leadership development and creating opportunities for local leaders is a core part of the company's strategy, differentiating it in a fragmented market [50][54]

Core Viewpoint - Enhabit (EHAB) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is influenced by changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The upgrade for Enhabit reflects an improvement in the company's underlying business, suggesting that investors may push the stock price higher due to this positive trend [5]. - For the fiscal year ending December 2025, Enhabit is expected to earn $0.50 per share, with a 9.3% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong track record of performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - Enhabit’s upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Group 1 - The Pennant Group, Inc. will participate in the 2025 Stephens Annual Investment Conference on November 19, 2025 [1] - Key executives including the CFO, COO, and President of the Senior Living segment will engage in a fireside chat during the conference [2] - A live webcast of the event will be available for interested parties [2] Group 2 - The Pennant Group operates 141 home health and hospice agencies and 61 senior living communities across multiple states in the U.S. [3] - Each operating subsidiary within the Pennant Group functions independently with its own management and assets [3] - The company emphasizes that it does not directly operate the individual businesses under its umbrella [3]

Core Insights - The Pennant Group, Inc. has acquired certain operations from UnitedHealth Group for a total purchase price of $146.5 million, which includes 54 locations primarily in Tennessee, Georgia, and Alabama [1][2][3] Group 1: Acquisition Details - The acquisition involves divested home health, hospice, and personal care services as part of an antitrust settlement between UnitedHealth and Amedisys with the U.S. Justice Department [1][2] - Approximately two-thirds of the revenue from the acquired agencies is related to home health services, while one-third is associated with hospice services [3] Group 2: Strategic Importance - This acquisition is viewed as a strategic move for Pennant, marking a new chapter in its growth journey and expanding its presence in the Southeast region [4] - The company aims to leverage proven leadership and operational excellence to integrate the new agencies into its existing platform [4] Group 3: Transition and Future Plans - A transition services agreement is in place to ensure a smooth integration process for the acquired operations [3] - The company plans to continue pursuing growth opportunities in the home health, hospice, and senior living sectors, focusing on strategic and underperforming operations [4]

Company Overview - Enhabit operates nationally across 34 states with approximately 10,600 employees[5] - As of June 30, 2025, Enhabit has 249 Home Health locations and 114 Hospice locations[6] - As of June 30, 2025, 108 Hospice locations are co-located with Home Health locations[7] Industry Trends and Advocacy - The 2028 Medicare skilled home health expenditures are projected to be approximately $41 billion[9] - The 2028 Medicare Hospice expenditures are projected to be approximately $32 billion[9] - Without home health access, mortality rate increases by 41%[19] - Without home health access, episodes with readmissions increase by 34%[19] - Without home health access, episodes with emergency room visits increase 16%[19] - Without home health access, total cost of care increases by approximately $2,500[19] Financial Performance and Debt Management - Home health non-Medicare admissions increased 5.2%[38] - Hospice average daily census grew 12.3% year over year[38] - Since Q1 2024, bank debt has been reduced by $70 million[39] - Leverage ratio decreased from Q4 2023, largely due to $75 million in bank debt reduction during this period[28]

Company Overview - Amedisys Inc. provides home health and hospice services across the U.S., catering to the growing chronic, co-morbid, and aging population [13] - The company offers clinically focused programs for chronic conditions such as diabetes and coronary artery disease, along with various rehabilitative programs [13] Zacks Rank and Style Scores - Amedisys holds a Zacks Rank of 3 (Hold) and has a VGM Score of A, indicating a strong overall rating [14] - The Value Style Score for Amedisys is B, supported by attractive valuation metrics, including a forward P/E ratio of 19.74 [14] - Recent upward revisions in earnings estimates by three analysts have increased the Zacks Consensus Estimate by $0.09 to $5.00 per share for fiscal 2025 [14] Investment Potential - Amedisys is highlighted as a stock to watch due to its solid Zacks Rank and top-tier Value and VGM Style Scores, making it a candidate for investors' short lists [15]

Core Viewpoint - Enhabit (EHAB) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The upgrade for Enhabit suggests an improvement in its underlying business, which could lead to increased stock prices as investors respond positively [5][10]. - For the fiscal year ending December 2025, Enhabit is expected to earn $0.44 per share, with the Zacks Consensus Estimate having increased by 18% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - Enhabit’s upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9][10].

Core Insights - Amedisys is expected to benefit from valuable partnerships and acquisitions that will generate significant synergies in the upcoming quarters, while facing challenges from a dull macroeconomic environment and competitive pressures [2][4][6] Company Performance - Amedisys shares have increased by 5.9% over the past year, outperforming the industry growth of 3.4% and the S&P 500's growth of 11% [3] - The company has a market capitalization of $3.18 billion and an earnings yield of 5.1%, which is higher than the industry's 4.2% [3] Strategic Initiatives - Amedisys is expanding its business through strategic partnerships and acquisitions, including participation in a new Medicare alternative payment model aimed at supporting dementia patients [4] - The company has introduced advanced molecular testing in collaboration with Patient Choice Laboratories to enhance diagnostic accuracy and speed [4] Clinical Quality - Amedisys has achieved an average Quality of Patient Care star rating of 4.18, with 88% of its care centers receiving 4 stars or higher, and 11 centers achieving a perfect 5-star rating [5][7] - The Patient Satisfaction star average stands at 4.02, exceeding the industry average [5] Market Challenges - The company faces macroeconomic pressures, including high labor costs due to inflation, which are expected to persist through 2025 [6] - Amedisys operates in a fragmented market with intense competition from local and hospital-owned providers, impacting its growth potential [8] Financial Estimates - The Zacks Consensus Estimate for Amedisys' 2025 earnings per share has decreased by 0.4% to $4.90, while the revenue estimate is projected at $2.46 billion, reflecting a 4.6% increase from the previous year [9]

Q1 2025 Highlights - Home health census showed sequential growth, exiting Q1 above the prior year quarter[12] - Hospice maintained monthly sequential Average Daily Census (ADC) growth for 14 consecutive months[12] - The company reduced its leverage ratio by 0.9x since Q1 2024, falling below 4.5x, ahead of the credit agreement requirement[12] Volume Trends - Home health total admissions decreased by 0.8% from Q1 2024 to Q1 2025[17] - Hospice ADC increased by 8.1% from Q1 2024 to Q1 2025[17] - Home health ADC increased by 2.1% from Q1 2024 to Q1 2025[17] Financial Performance - Home Health Adjusted EBITDA Margin was 17.7% in Q1 2025[19] - The company's net debt to adjusted EBITDA leverage ratio decreased by 0.9 from FY 2023 to Q1 2025[19] - Home Health Medicare revenue as a percentage of segment revenue is declining, with a Q1 2025 value of 55.7%[19] Industry Outlook - The aging population is expected to grow, with a 5% expected annual growth in the target population over the next three years[22] - Home health care is presented as a cost-efficient alternative, with an average Medicare cost per day of $63, compared to $556 for skilled nursing facilities[22]